Repository logo
 
Publication

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen

2014Journal article Open access
Simple item page
dc.contributor.authorCavaco-Silva, J
dc.contributor.authorAbecasis, A
dc.contributor.authorMiranda, AC
dc.contributor.authorPoças, J
dc.contributor.authorNarciso, J
dc.contributor.authorÁguas, MJ
dc.contributor.authorMaltez, F
dc.contributor.authorAlmeida, I
dc.contributor.authorGermano, I
dc.contributor.authorDiniz, A
dc.contributor.authorGonçalves, MF
dc.contributor.authorGomes, P
dc.contributor.authorCunha, C
dc.contributor.authorCamacho, RJ
dc.date.accessioned2014-04-02T11:50:18Z
dc.date.available2014-04-02T11:50:18Z
dc.date.issued2014
dc.description.abstractTo characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen. All patients were infected by HIV-2 group A. 61.4% of the integrase residues were conserved, including the catalytic motif residues. No INSTI-major resistance mutations were detected in the virus population from naïve patients, but two amino acids that are secondary resistance mutations to INSTIs in HIV-1 were observed. The 10 raltegravir-experienced patients exhibited resistance mutations via three main genetic pathways: N155H, Q148R, and eventually E92Q - T97A. The 155 pathway was preferentially used (7/10 patients). Other mutations associated to raltegravir resistance in HIV-1 were also observed in our HIV-2 population (V151I and D232N), along with several novel mutations previously unreported. Data retrieved from this study should help build a more robust HIV-2-specific algorithm for the genotypic interpretation of raltegravir resistance, and contribute to improve the clinical monitoring of HIV-2-infected patients.por
dc.identifier.citationPLoS One. 2014 Mar 28;9(3):e92747por
dc.identifier.urihttp://hdl.handle.net/10400.17/1771
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherPLOS Onepor
dc.subjectHCC INFpor
dc.subjectDrug Resistance, Viral/geneticspor
dc.subjectGenotypepor
dc.subjectHIV Infections/drug therapy
dc.subjectHIV Integrase/genetics
dc.subjectHIV Integrase Inhibitors/therapeutic use
dc.subjectHIV-1/drug effects
dc.subjectHIV-2/drug effects
dc.subjectHIV-2/genetics
dc.subjectPolymorphism, Genetic/genetics
dc.subjectPyrrolidinones/therapeutic use
dc.titleHIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimenpor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titlePlos Onepor
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Plos One.pdf
Size:
290.36 KB
Format:
Adobe Portable Document Format
Download

Collections

INF - Artigos